Adverse events associated with health food use appear to be quite common. Nevertheless, even though severe adverse events should be reported to the Japanese government via public health centers, the number of cases reported is relatively small. To clarify this discrepancy and to understand how consumers and physicians act when they or their patients develop adverse events due to health food use, we conducted an internet questionnaire with consumers (preliminary survey: n=44,649; full survey: n=3,000), physicians (n=500), and pharmacists (n=500). During 2016, 17% of consumers who used health foods developed adverse events. However, only 11% of them reported their adverse events to public health centers. Most physicians and pharmacists did not report these cases to public health centers because they were unable to establish a clear cause-and-effect relationship. It is important to encourage not only consumers, but also physicians and pharmacists to report adverse events to public health centers.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3358/shokueishi.58.234 | DOI Listing |
Cancer Res Treat
December 2024
Department of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
Purpose: Daratumumab is a novel, first-in-class monoclonal antibody approved for use as monotherapy and in combination with other treatments for patients with multiple myeloma (MM). The aim of this observational study was to evaluate the effectiveness and safety of daratumumab in real-world clinical practice.
Materials And Methods: This observational multicenter study collected data from patients with MM treated in Korea between June 1, 2018, and February 28, 2022.
Cancer Res Treat
December 2024
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Purpose: Fentanyl, a highly lipophilic opioid, was developed as a sublingual fentanyl tablet (SFT) for the management of breakthrough cancer pain (BTcP), and its efficacy and safety were confirmed in a randomized, controlled study. We investigated the effectiveness and safety of SFT administered to alleviate BTcP in a real-world setting.
Materials And Methods: In this prospective, open, single-cohort study, conducted in 13 referral hospitals in South Korea, opioid-tolerant cancer patients receiving around-the-clock opioids for persistent cancer pain were enrolled if the individual had BTcP ≥ 1 episode/day during the preceding week.
Cancer Res Treat
December 2024
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Purpose: Platinum-based chemotherapy is the standard treatment for advanced urothelial carcinoma (aUC). Switch maintenance therapy after first-line (1L) treatment may delay disease progression. This study evaluated pemetrexed as switch maintenance therapy versus observation in aUC patients without disease progression after initial chemotherapy.
View Article and Find Full Text PDFTrans R Soc Trop Med Hyg
December 2024
Executive Director & Chief Executive Officer, All India Institute of Medical Sciences, Deoghar, Jharkhand, India.
Background: This study aimed to evaluate mass drug administration (MDA) coverage for lymphatic filariasis (LF) in selected endemic districts of Jharkhand, India, and to identify household-level determinants of drug consumption.
Methods: A cross-sectional coverage evaluation survey was conducted in the Deoghar, Giridih and Godda districts of Jharkhand in 2023 within 6 wk of the completion of the MDA campaign. The survey included 9039 individuals from 1680 households across 56 randomly selected clusters (three urban, eight tribal and 45 rural).
Expert Opin Drug Saf
December 2024
Zhejiang Academy of Traditional Chinese Medicine, Tongde hospital of Zhejiang Province, Hangzhou, Zhejiang, China.
Background: Aducanumab, a monoclonal antibody, received approval for the treatment of Alzheimer's disease in 2021. However, it remains controversial over the security of this drug. In this study, aducanumab-related adverse events (AEs) were evaluated through data mining based on the FDA Adverse Event Reporting System (FAERS) database.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!